SHANGHAI
EpimAb Biotherapeutics, an emerging biopharmaceutical company based in Shanghai, announced today that the United States Patent and Trademark Office (USPTO) has granted the U.S. Patent No. 10,266,608 entitled “Fabs-In-Tandem Immunoglobulin and Uses Thereof”. Based on EpimAb’s globally filed first application, this patent broadly covers bispecific antibodies obtained utilizing the company’s FIT-Ig® technology in a composition of matter claim.
“This patent underscores the novelty of EpimAb’s approach in bispecific antibody generation and forms an important foundation of EpimAb’s growing IP portfolio,” said Dr. Chengbin Wu, Founder and CEO of EpimAb Biotherapeutics. “The first granted patent in a major pharmaceutical market like the US therefore represents a significant milestone for EpimAb and takes us another step towards our goal to become a leading innovator in cancer biologics.”
EpimAb is developing multiple programs based on its FIT-Ig® platform for the treatment of various cancers. Its most advanced product candidate EMB-01, a cMet/EGFR bispecific with a novel mechanism of action was discovered and rapidly developed to the clinic by EpimAb. It is currently being investigated in a clinical Phase I/II trial in the USA and China. A second FIT-Ig molecule is currently under preclinical development with further molecules following soon, rapidly growing EpimAb’s pipeline of bispecific antibodies.
About EpimAb Biotherapeutics, Inc.
EpimAb Biotherapeutics is a privately-owned biopharmaceutical R&D company based in Shanghai and Suzhou with a proprietary unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) to generate bispecific molecules with antibody-like properties, without any mutations, peptide linkers, or non-Ig sequences. With this platform EpimAb is creating a pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is also committed to diversifying its pipeline through selective licensing of its platform to partners worldwide. For further information, please visit www.epimab.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190423005880/en/
CONTACT
EpimAb Biotherapeutics
Dr. Stephan Lensky, COO/CBO
Direct:
+49 152 2610 7621
E-Mail: Stephan.lensky@epimab.com
Media Inquiries
Mario Brkulj or Amanda Houlihan
Direct:
+49 175 5711562 or +1 781 235 3060
E-Mail: epimab@macbiocom.com
